J 2009; 34(3):770–1.156 156 Lee WT, Kirkham N, Johnson MK, Lordan JL, Fisher AJ, Peacock AJ. Sitaxentan‐related acute liver failure in a patient with pulmonary arterial hypertension. Eur Respir J 2011; 37(2):472–4.
157 157 Hoeper MM, Olsson KM, Schneider A, Golpon H. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009; 33(6):1518–9.
158 158 Owen K, Cross DM, Derzi M, Horsley E, Stavros FL. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin(R)), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. Regul Toxicol Pharmacol 2012; 64(1):95–103.
159 159 Erve JC, Gauby S, Maynard JW, Jr., Svensson MA, Tonn G, Quinn KP. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Chem Res Toxicol 2013; 26(6):926–36.
160 160 Whitley RJ. Sorivudine: a potent inhibitor of varicella zoster virus replication. Adv Exp Med Biol 1996; 394:41–4.
161 161 Whitley RJ. Sorivudine: a promising drug for the treatment of varicella‐zoster virus infection. Neurology 1995; 45 (12 Suppl 8):S73–5.
162 162 Burdge DR, Voigt R, Lindley JI, Gage L, Sacks SL. Sorivudine (BV‐ara‐U) for the treatment of complicated refractory varicella zoster virus infection in HIV‐infected patients. AIDS 1995; 9(7):810–2.
163 163 Pinnolis MK, Foxworthy D, Kemp B. Treatment of progressive outer retinal necrosis with sorivudine. Am J Ophthalmol 1995; 119(4):516–7.
164 164 Wunderli W, Miner R, Wintsch J, von Gunten S, Hirsch HH, Hirschel B. Outer retinal necrosis due to a strain of varicella‐zoster virus resistant to acyclovir, ganciclovir, and sorivudine. Clin Infect Dis 1996; 22(5):864–5.
165 165 Bodsworth NJ, Boag F, Burdge D, Genereux M, Borleffs JC, Evans BA, et al. Evaluation of sorivudine (BV‐araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus‐infected adults. The Multinational Sorivudine Study Group. J Infect Dis 1997; 176(1):103–11.
166 166 Okuda H, Nishiyama T, Ogura K, Nagayama S, Ikeda K, Yamaguchi S, et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5‐fluorouracil prodrugs. Drug Metab Dispos 1997; 25(5):270–3.
167 167 Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5‐fluorouracil prodrugs. J Pharmacol Exp Ther 1998; 287(2):791–9.
168 168 Diasio RB. Sorivudine and 5‐fluorouracil; a clinically significant drug‐drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol 1998; 46(1):1–4.
169 169 Dawson RM. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci Lett 1990; 118(1):85–7.
170 170 Summers WK, Koehler AL, Marsh GM, Tachiki K, Kling A. Long‐term hepatotoxicity of tacrine. Lancet 1989; 1(8640):729.
171 171 Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271 (13):992–8.
172 172 Fredj G, Dietlin F, Barbier G, Jasmin C, Bonhomme L, Esctein S, et al. Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS. Therapie 1992; 47(3):245–7.
173 173 Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996; 10(2):156–7.
174 174 Madden S, Woolf TF, Pool WF, Park BK. An investigation into the formation of stable, protein‐reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes. Biochem Pharmacol 1993; 46(1):13–20.
175 175 Hendrickson HP, Scott DO, Lunte CE. Identification of 9‐hydroxylamine‐1,2,3,4‐tetrahydroacridine as a hepatic microsomal metabolite of tacrine by high‐performance liquid chromatography and electrochemistry. J Chromatogr 1989; 487(2):401–8.
176 176 Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck‐Brentano C, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61(6):619–27.
177 177 Pool WF, Reily MD, Bjorge SM, Woolf TF. Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metab Dispos 1997; 25(5):590–7.
178 178 Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF, Park BK. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995; 25(1):103–16.
179 179 Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK, et al. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: evidence of involvement of multiple organic cation transporters in the transport. Drug Metab Dispos 2005; 33(3):440–8.
180 180 Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB. The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology 1996; 23(6):1429–35.
181 181 Simon T, Becquemont L, Mary‐Krause M, de Waziers I, Beaune P, Funck‐Brentano C, et al. Combined glutathione‐S‐transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin Pharmacol Ther 2000; 67(4):432–7.
182 182 Becquemont L, Lecoeur S, Simon T, Beaune P, Funck‐Brentano C, Jaillon P. Glutathione S‐transferase theta genetic polymorphism might influence tacrine hepatotoxicity in Alzheimer's patients. Pharmacogenetics 1997; 7(3):251–3.
183 183 Biglin KE, Faraon MS, Constance TD, Lieh‐Lai M. Drug‐induced torsades de pointes: a possible interaction of terfenadine and erythromycin. Ann Pharmacother 1994; 28(2):282.
184 184 Wynn RL. Erythromycin and ketoconazole (Nizoral) associated with terfenadine (Seldane)‐induced ventricular arrhythmias. Gen Dent 1993; 41(1):27–9.
185 185 Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR, Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52(3):231–8.
186 186 Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269 (12):1532–6.
187 187 Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine‐ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269 (12):1513–8.
188 188 Zimmermann M, Duruz H, Guinand O, Broccard O, Levy P, Lacatis D, et al. Torsades de Pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13(7):1002–3.
189 189 Kamisako T, Adachi Y, Nakagawa H, Yamamoto T. Torsades de pointes associated with terfenadine in a case of liver cirrhosis and hepatocellular carcinoma. Intern Med 1995; 34(2):92–5.
190 190 Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine HCl. Clin Exp Allergy 1999; 29 Suppl 3:163–70; discussion 71‐3.
191 191 Balian JD, Rahman A. Metabolic drug‐drug interactions: perspective from FDA medical and clinical pharmacology reviewers. Adv Pharmacol 1997; 43:231–8.
192 192 Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, et
